|
|
|
1)
|
Sheenan DV. Why Sustained-Release Medications? Practical Considerations in the Management of Patients With Anxiety. Psych. Annals 1993; October (suppl.): 3-6.
Stahl SM. Alprazolam-XR: Dosage considerations. Psych. Annals. 1993; (suppl.): 27-31.
Alexander PE. The need for Extended-Release Medications, Current Therapeutic Research, Vol. 56, No. 9, 1995: 940-946.
Klein E. Discontinuation of Benzodiazepines in Patients with anxiety disorders: A focus on Alprazolam extended release. Current Therapeutic Research, Vol. 56, No. 9, 1995: 969-974.
Massana J. Sat. Symposium: Extended Release Alprazolam: A new Approach to the Management of Anxiety Disorders: WCP, Madrid, August 1996.
|
| 2) |
Alexander PE. Current Therapeutic Research, Vol. 56, No. 9, 1995: 940-946. |
| 3) |
Stahl SM. Psych. Annals; October 1993; (suppl.): 27-31. Alexander PE. Current Therapeutic Research, Vol. 56, No. 9, 1995: 940-946.
Alexander PE. Psych. Annals; October 1993; (suppl.): 14-19.
Schweizer E. Psych. Annals; October 1993; (suppl.): 32-37. |
| 4) |
Evans RL. Alprazolam-XR: A pharmacokinetic Review. Psych. Annals; October 1993; (suppl.): 8-12. |
| 5) |
Pecknold J et al. Alprzolam-XR in the Management of Anxiety: Discontinuation. Psych. Annals; October 1993; (suppl.): 38-44. |
| 6) |
Schatzberg AF. Short- and Long-term discontinuation of alprazolam in patients with panic disorders with agoraphobia. Sat. Symposium: Extended-Release Alprazolam: A new Approach to the Management of Anxiety Disorders. WCP, Madrid, August 1996. |
| 7) |
Geoffrey K, Mumford et al. Alprazolam absorption kinetics affects abuse liability Clinical Pharmacology & therapeutics. Volume 57; No. 3; 1995: 356-336. |
|
|
|
